Información del artículo
Abstract
Introduction
Dermatomyositis (DM) is an autoimmune disease included in the group of idiopathic inflammatory myopathies. Markers of disease activity are needed for clinical control in order to facilitate adjustment of immunomodulatory therapy. We analyzed the relationship between complement activation products (CAP) and the activity of dermatomyositis and its usefulness in the follow-up of the disease and the prediction of recrudescences related to usual biochemical parameters.
Material and methodsWe studied 16 patients with DM that were followed periodically. In each appointment the degree of cutaneous and muscular activity was assessed and such disease activity was correlated with plasma levels of C3a and C5b-9, measured by ELISA.
ResultsThough we obtained certain correlation between disease activity and plasma levels of C3a and C5b-9, the strength of such correlation was not superior to that obtained by usual biochemical markers. C3a was shown to be the most sensitive marker (100%) with a sufficient specificity (83.3%) in the capability to predict recrudescences.
ConclusionsC3a and, to a lesser extent C5b-9, would be useful in the identification of patients with especially active DM as well as in predicting disease recrudescences. Nevertheless they are not superior to the rest of biochemical markers as indicators of current activity.
Key words:
dermatomyositis
activity
recrudescence
complement system
C3a
C5b-9
creatine phosphokinase
Resumen
Introducción
La dermatomiositis (DM) es una enfermedad de origen autoinmune, incluida en el grupo de las miopatías inflamatorias idiopáticas. En el control clínico de este proceso se precisan marcadores que permitan determinar el grado de actividad de la enfermedad, facilitando así el ajuste a la terapia inmunomoduladora. Se analiza la relación entre los productos de activación del complemento (PAC) y la actividad de la DM y su utilidad en el seguimiento de la enfermedad y en la predicción de las reagudizaciones en relación a los parámetros bioquímicos habituales.
Material y métodosSe estudiaron 16 pacientes con DM, que fueron seguidos periódicamente. En cada revisión se estableció el grado de actividad cutánea y muscular del proceso, y se correlacionó dicha actividad con los niveles plasmáticos de C3a y C5b-9, determinados mediante técnica de ELISA.
ResultadosSi bien se obtuvo cierta correlación entre la actividad del proceso y los niveles plasmáticos de C3a y C5b-9, la intensidad de dicha correlación no superó la obtenida por los marcadores bioquímicos tradicionales. En la capacidad de predicción de reagudizaciones, C3a se mostró como el marcador más sensible (100%), con una especificidad suficiente (83,3%).
ConclusionesC3a y en menor medida C5b-9 serían de utilidad en la identificación de pacientes con DM especialmente activas, así como en la predicción de reagudizaciones del proceso. Sin embargo, no tienen una utilidad superior al resto de marcadores bioquímicos como marcadores de actividad actual.
Palabras clave:
dermatomiositis
actividad
reagudización
sistema del complemento
C3a
C5b-9
creatinfosfoquinasa
El Texto completo está disponible en PDF
References
[2.]
R. Wortmann.
Inflammatory diseases of muscle and other myopathies.
Kelley's Textbook of Rheumatology, 6th ed., pp. 1273-1296
[3.]
M.C. Dalakas.
Polymyositis, dermatomyositis and inclusion body-myositis.
N Engl J Med, 325 (1991), pp. 1487-1498
[4.]
M.C. Dalakas.
Polymyositis, dermatomyositis and inclusion body myositis.
Harrison's principles of internal medicine, 15th ed., pp. 2524-2529
[5.]
J.S. Resnick, M. Mammel, M.O. Mundale, F.J. Kottke.
Muscular strength as an index of response to therapy in childhood dermatomyositis.
Arch Phys Med Rehabil, 62 (1981), pp. 12-19
[6.]
M. Miranda, A. Carvallo.
Juvenile dermatomyositis: clinical manifestations and laboratory tests.
Rev Chil Pediatr, 62 (1991), pp. 28-33
[7.]
R. Devere, W.G. Bradley.
Polymyositis: its presentation morbidity and mortality.
Brain, 98 (1975), pp. 637-666
[8.]
L.M. Pachman, J.R. Hayford, J. Sinacore, S.L. Bowyer, M.C. Hochberg.
New onset juvenile dermatomyositis: a clinical description.
Arthritis Rheum, 35 (1992), pp. S88
[9.]
J. Guzman, R.E. Petty, P.N. Malleson.
Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes.
J Rheumatol, 21 (1994), pp. 739-743
[10.]
C. Dorph, I. Nennesmo, I.E. Lundberg.
Percutaneous conchotome muscle biopsy. A useful diagnostic and assessment tool.
J Rheumatol, 28 (2001), pp. 1591-1599
[11.]
E. Szmidt-Salkowska, K. Rowinska-Marcinska, R.E. Lovelace.
EMG dynamics in polymyositis and dermatomyositis in adults.
Electomyogr Clin Neurophysiol, 29 (1989), pp. 399-404
[12.]
L.G. Rider, R.C. Gurley, J.P. Pandey.
Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy.
Arthritis Rheum, 41 (1998), pp. 710-719
[13.]
D.J. Wallace, A.L. Metzger, K.K. White.
Combination immunosupressive treatment of steroid resistant dermatomyositis/polymyositis.
Arthritis Rheum, 28 (1985), pp. 590-592
[14.]
R. Mader, E.C. Keystone.
Inflammatory myopathy. Do we have adequate measures of the treatment response?.
J Rheumatol, 20 (1993), pp. 1105-1107
[15.]
L.J. Kagen.
Myoglobinemia and myoglobinuria in patients with myositis.
Arthritis Rheum, 14 (1971), pp. 457-464
[16.]
M. Nishikai, M. Reichlin.
Radioimmunoassay of serum myoglobin in polymyositis and other conditions.
Arthritis Rheum, 20 (1977), pp. 1514-1518
[17.]
J.C.C. Borleffs, R.H.W.M. Dersken, D.P. Bar.
Serum myoglobin and creatine kinase concentrations in patients with polymyositis or dermatomyositis.
Ann Rheum Dis, 46 (1987), pp. 173-175
[18.]
A. Kadoya, J. Okada, H. Kondo.
Serum hepatocyte growth factor in patients with inflammatory myopathies.
Nihon Rinsho Meneki Gakkai Kaishi, 19 (1996), pp. 488-497
[19.]
D.D. Fraser, J.A. Frank, M. Dalakas, F.W. Miller, J.E. Hicks, P. Plotz.
MRI in the idiopathic inflammatory myopathies.
J Rheumatol, 18 (1991), pp. 1693-1700
[20.]
R.J. Hernández, D.R. Keim, T.L. Chenevert, D.B. Sullivan, A.M. Aisen.
Fat-suppressed MR imaging for myositis.
Radiology, 182 (1992), pp. 217-219
[21.]
M. Nishikai, K. Akiya.
Clinical significance of magnetic resonance imaging of skeletal muscles in idiopathic inflammatory myopathies of adults.
Ryumachi, 40 (2000), pp. 881-890
[22.]
S.M. Maillard, R. Jones, C. Owens, C. Pilkington, P. Woo, L.R. Wedderburn, et al.
Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis.
Rheumatology (Oxford), 43 (2004), pp. 603-608
[23.]
M. Lofberg, K. Liewendahl, A. Lamminen, O. Korhola, H. Somer.
Antimyosin scintigraphy compared with magnetic resonance imaging in inflammatory myopathies.
Arch Neurol, 55 (1998), pp. 987-993
[24.]
M.C.P. Van Beekvelt, R.A. Wevers, B.G. van Engelen, W.N.J.M. Colier.
Muscle tissue oxygenation as a functional tool in the follow up of dermatomyositis.
J Neurol Neurosurg Psychiatry, 73 (2002), pp. 93-94
[25.]
J.E. Hicks, B. Drinkard, R.M. Summers, L.G. Rider.
Decreased aerobic capacity in children with juvenile dermatomyositis.
Arthritis Rheum, 47 (2002), pp. 118-123
[26.]
C.A. Buchpiguel, S. Roisenblatt, M.F. Lucena-Fernandes.
Radioisotopic assessment of peripheral and cardiac muscle imvolvement and dysfunction in polymyositis/dermatomyositis.
J Rheumatol, 18 (1991), pp. 1359-1363
[27.]
T. Komiya, N. Negoro, K. Kondo, K. Miura, Y. Hirota, J. Yoshikawa.
Clinical significance of von Willebrand factor in patients with adult dermatomyositis.
Clin Rheumatol, 24 (2005), pp. 352-357
[28.]
J.P. Scott, C. Arroyave.
Activation of complement and coagulation in juvenile dermatomyositis.
Arthritis Rheum, 30 (1987), pp. 572-576
[29.]
S. Bowyer, C. Ragsdale, D. Sullivan.
Factor VIII-related antigen and childhood rheumatic diseases.
J Rheumatol, 16 (1989), pp. 1093-1097
[30.]
B.J. Bloom, L.B. Tucker, L.C. Miller, J.G. Schaller.
Von Willebrand factor in juvenile dermatomyositis.
J Rheumatol, 22 (1995), pp. 320-325
[31.]
P. Mercie, M. Seigneur, J. Constans, M. Boisseau, C. Conri.
Assay of plasma thrombomodulin in systemic diseases.
Rev Med Interne, 18 (1997), pp. 126-131
[32.]
F. DeBenedetti, M. DeAmici, L. Aramini, N. Ruperto, A. Martini.
Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis.
Arch Dis Child, 69 (1993), pp. 232-235
[33.]
B.L. Myones, J.P. Luckey, J.R. Hayford, L.M. Pachman.
Increased neopterin levels in juvenile dermatomyositis correlate with disease activity and are indicative of macrophage activation.
Arthritis Rheum, 32 (1989), pp. S83
[34.]
L.M. Pachman, D. Dilling, D.L. Litt, M.L. Miller, J.S. Sinacore.
Sequential studies of neopterin, von Willebrand factor antigen (vWF:Ag) creatine kinase (CK) and aldolase in juvenile dermatomyositis.
Arthritis Rheum, 35 (1993), pp. S257
[35.]
M.Y. Samsonov, E.L. Nassonov, G.P. Tilz, B.M. Geht, U. Dermel, G.T. Gurkina, et al.
Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis.
Br J Rheumatol, 36 (1997), pp. 656-660
[36.]
E.L. Nasonov, M.I. Samsonov, G. Tilz, D. Fuchs.
Neopterin: new immunological marker of autoimmune rheumatic disease.
Klin Med, 78 (2000), pp. 43-46
[37.]
F.W. Miller, L.A. Love, A. Barbieri, J.E. Balow, P.H. Plotz.
Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups.
Clin Exp Immunol, 81 (1990), pp. 373-379
[38.]
A.E. Kalovidouris.
The role of cytokines in polymyositis: interferon-gamma induces class II and enhances class I major histocompatibility complex antigen expression on cultured human muscle cells.
J Lab Clin Med, 120 (1992), pp. 244-251
[39.]
R.E. Wolf, B.A. Baethge.
Interleukin-1α, interleukin-2, and soluble interleukin-2 receptor in polymyositis.
Arthritis Rheum, 33 (1990), pp. 1007-1014
[40.]
Y. Tokano, Y. Kanai, H. Hashimoto, K. Okomura, S. Hirose.
Soluble interleukin 2 receptors in patients with polymyositis/dermatomyositis.
Ann Rheum Dis, 51 (1992), pp. 781-782
[41.]
R. González-Amaro, J. Alcocer-Varela, D. Alarcón-Segovia.
Natural killer cell activity in dermatomyositis-polymyositis.
J Rheumatol, 14 (1987), pp. 307-310
[42.]
D.M. Eisenstein, M.R. O’Gorman, L.M. Pachman.
Correlation between change in disease activity and changes in perpheral blood lymphocyte subsets in patients with juvenile dermatomyositis.
J Rheumatol, 24 (1997), pp. 1830-1832
[43.]
E.J. Walker, P.D. Jeffrey, J. Webb, K.E. Tymms.
Polydermatomyositis with anti-PL7 antibody: clinical and laboratory follow-up over a five-year period.
Clin Exp Rheumatol, 7 (1989), pp. 537-540
[44.]
G. Cambridge, E. Ovadia, D.A. Isenberg, V. Dubowitz, J. Sperling, R. Sperling.
Juvenile dermatomyositis: serial studies of circulating autoantibodies to a 56kD nuclear protein.
Clin Exp Rheumatol, 12 (1994), pp. 451-457
[45.]
H. Arad-Dann, D. Isenberg, E. Ovadia, Y. Shoenfeld, J. Sperling, R. Sperling.
Autoantibodies against a nuclear 56-kDa protein: a marker for inflammatory muscle disease.
J Autoimmun, 2 (1989), pp. 877-888
[46.]
A. Parodi, M. Caproni, A.V. Marzano, C. De Simone, M. La Placa, P. Quaglino.
Dermatomyositis in 132 patients with different clinical subtypes: cutaneous signs, constitutional symptoms and circulating antibodies.
Acta Derm Venereol, 82 (2002), pp. 48-51
[47.]
C. Gabay, F. Gay-Croisier, P. Roux-Lombard, O. Meyer, C. Maineti, P.A. Guerne, et al.
Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response.
Arthritis Rheum, 37 (1994), pp. 1744-1751
[48.]
A.M. Prieur, A. Dayer, P. Roux-Lombard, J.M. Dayer.
Levels of cytokine inhibitors: a possible marker of disease activity in childhood dermatomyositis and polymyositis.
Clin Exp Rheumatol, 15 (1997), pp. 211-214
[49.]
K. Son, Y. Tomita, T. Shimizu, S. Nishinarita, S. Sawada, T. Horie.
Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis.
Intern Med, 39 (2000), pp. 128-135
[50.]
M. Kubo, H. Ihn, K. Yamane, N. Yazawa, K. Kikuchi, Y. Soma, et al.
Increased serum levels of soluble vascular cell adhesion molecule-1 and soluble E-selectin in patients with polymyositis/dermatomyositis.
Br J Dermatol, 143 (2000), pp. 392-398
[51.]
B.J. Bloom, L.C. Miller, P.R. Blier.
Soluble adhesion molecules in pediatric rheumatic diseases.
J Rheumatol, 29 (2002), pp. 832-836
[52.]
M. Kubo, H. Ihn, A. Matsukawa, K. Kikuchi, K. Tamaki.
Dermatomyositis with elevated serum hyaluronate.
Clin Exp Dermatol, 24 (1999), pp. 275-278
[53.]
M. Kubo, K. Kikuchi, M. Fujimoto, K. Tamaki.
Serum concentrations of carboxyterminal propeptide of type 1 procollagen and tissue inhibitor of metalloproteínase 1 in patients with dermatomyositis.
Arch Dermatol Res, 290 (1998), pp. 253-257
[54.]
K. Mokuno, K. Kiyosawa, H. Hond, Y. Hirose, T. Murayama, S. Yoneyama, et al.
Elevated serum levels of manganese superoxide dismutase in polymyositis and dermatomyositis.
Neurology, 46 (1996), pp. 1445-1447
[55.]
J. Liu, J. Li, N. Zhai, L. Geng, F. Song.
Detection of the levels of neuropeptides, ACTH and cortisol in the blood of patients with polymyositis/dermatomyositis and their significance.
J Dermatol, 31 (2004), pp. 392-397
[56.]
J.N. Whitaker, W.K. Engel.
Vascular deposits of immunoglobulin and complement in idiopathic inflammmatory myopathy.
N Engl J Med, 286 (1972), pp. 333-338
[57.]
B.Q. Banker, M. Victor.
Dermatomyositis (systemic angiopathy) of childhood.
Medicine, 45 (1966), pp. 261-289
[58.]
F. Jerusalem, M. Radusa, A.G. Engel, R.D. MacDonald.
Morphometric analysis of skeletal muscle capillary ultrastructure in inflammatory myopathies.
J Neurol Sci, 23 (1974), pp. 391-402
[59.]
B.Q. Banker.
Dermatomyositis of childhood: ultrastructural alterations of muscle and intramuscular blood vessels.
N Neuropahtol Exp Neurol, 34 (1975), pp. 56-75
[60.]
S. Carpenter, G. Karpati, S. Rothman, G. Watters.
The childhood type of dermatomyositis.
Neurology, 26 (1976), pp. 952-962
[61.]
F.E. Batten.
Case of dermato-myositis in a child, with pathological report.
Br J Child Dis, 9 (1912), pp. 247-257
[62.]
R. Estruch, J.M. Grau, J. Fernández Solá, J. Casademont, R. Monforte, A. Urbano-Márquez.
Microvasular changes in skeletal muscle in idiopathic inflammatory myopathy.
Human Pathol, 23 (1992), pp. 888-895
[63.]
J.T. Kissel, J.R. Mendell, K.W. Rammohan.
Microvascular deposition of complement attack complex in dermatomyositis.
N Engl J Med, 314 (1986), pp. 329-334
[64.]
J.T. Kissel, R.K. Halterman, W. Kottil, M.D. Rammohan, J.R. Mendell.
The relationship of complement-mediated microvasulopathy to the histologic features and clinical duration of disease in dermatomyositis.
Arch Neurol, 48 (1991), pp. 26-30
[65.]
A.M. Emslie-Smith, A.G. Engel.
Microvascular changes in early and advanced dermatomyositis: a quantitative study.
Ann Neurol, 27 (1990), pp. 343-356
[66.]
M. De Visser, A.M. Emslie-Smith, A.G. Engel.
Early ultrastructural alterations in adult dermatomyositis.
J Neurol Sci, 94 (1989), pp. 181-192
[67.]
M. Basta, I. Illa, M.C. Dalakas.
Increased invitro uptake of complement C3b in the serum of patients with Guillain-Barré syndrome, myasthenia gravis and dermatomyositis.
J Neuroimmunol, 71 (1996), pp. 227-229
[68.]
M.R. Stonecipher, J.L. Jorizzo, W.L. White.
Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: dermatomyositis sine myositis?.
J Am Acad Dermatol, 28 (1993), pp. 951-956
[69.]
S. Manzi, J.E. Rairie, A.B. Carpenter, R.H. Kelly, S.P. Jagarlapudi, S.M. Sereika, et al.
Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
Arthritis Rheum, 39 (1996), pp. 1178-1188
[70.]
J.P. Buyon, J. Tamerius, H.M. Belmont, S.B. Abramson.
Assessment of disease activity and impending flare in patients with systemic lupus erythematosus.
Arthritis Rheum, 35 (1992), pp. 1028-1037
[72.]
R.K. Bode, M.S. Klein-Gitelman, M.L. Miller, T.S. Lechman, L.M. Pachman.
Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence.
Arthritis Care Res, 49 (2003), pp. 7-15
[73.]
D.M. Ricker, L.A. Hebert, R. Rhode, D.D. Sedmak, E.J. Lewis, J.D. Clough, The Lupus Nephritis Collaborative Study Group.
Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels.
Am J Kidney Dis, 18 (1991), pp. 678-685
[74.]
T.E. Mollnes, H.J. Haga, J.G. Brun, E.W. Nielsen, A. Sjoholm, G. Sturfeldt, et al.
Complement activation in patients with systemic lupus erythematosus without nephritis.
Rheumatol, 38 (1999), pp. 933-940
[75.]
J.M. Porcel, J. Ordi, A. Castro Salomo, M. Vilardell, M.J. Rodrigo, T. Gene, et al.
The value of complement activation products in the assessment of systemic lupus erythematosus flares.
Clin Immunol Immunopathol, 74 (1995), pp. 283-288
Copyright © 2007. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
